Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) reported treatment of the first patient in cohort 5 of its Phase 1 FSHR-targeted CAR-T/CER-T trial for recurrent ovarian cancer at Moffitt Cancer Center.
The study has escalated to 1×10⁷ CAR-positive cells/kg, with no dose-limiting toxicities observed to date and five patients surviving 13–28 months post-treatment.
Positive
- Dose escalated to 1×10⁷ CAR-positive cells/kg in cohort 5
- No dose-limiting toxicities observed through 3×10⁶ CAR-T cells/kg
- Five treated patients survived approximately 13–28 months post-treatment
- Therapy targets FSHR, with limited expression in healthy tissues
Negative
- Data are from an early-stage Phase 1 safety trial
- Efficacy evidence limited to small number of treated patients so far
Market reaction after Phase 1 ovarian CAR-T dose escalation: ANIX -6.73% in the Jul 6 session
In the Jul 6 session, ANIX declined 6.73%, reflecting a notable negative market reaction. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 26 | Clinical data update | Positive | +6.5% | Updated breast cancer vaccine and ovarian CAR-T data presented at oncology symposium. |
| May 11 | CAR-T survival data | Positive | +1.0% | Updated survival and safety from ongoing Phase 1 lira-cel ovarian cancer trial. |
| Apr 01 | Phase 1 results | Positive | +5.4% | Positive final Phase 1 breast cancer vaccine results and move toward Phase 2. |
| Mar 30 | Trial presentation notice | Neutral | -2.0% | Announcement of upcoming ovarian cancer CAR-T trial presentation at SGO meeting. |
| Dec 11 | Phase 1 data | Positive | -25.4% | Final positive Phase 1 breast cancer vaccine data with strong immune responses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most prior clinical trial updates were received positively, though one major positive data release coincided with a sharp selloff.
Key Terms
car-t medical
fshr medical
lymphodepletion medical
dose-limiting toxicities medical
follicle stimulating hormone receptor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date
Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion
The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on ovarian cancer cells but has limited expression in healthy tissues. The trial is designed to assess safety, tolerability, and preliminary signs of efficacy across escalating dose levels.
The patient received a dose of 1×10⁷/kg CAR-positive cells following lymphodepletion, representing the highest dose level evaluated to date in the study. To date, no dose-limiting toxicities have been observed across any cohort up to and including the dose level of 3x106/kg CAR-T cells, the prior dose tested.
As of the date of this release, five patients in the study have surpassed one year of survival following treatment, with individual patients surviving approximately 28, 20, 17, 17, and 13 months post-treatment, respectively. The Company believes these outcomes are notable in a highly pre-treated, recurrent ovarian cancer population that has progressed after multiple prior lines of therapy and limited treatment options and poor prognosis.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "Advancing to the fifth cohort and highest dose level while observing no dose-limiting toxicities across the study to date is a meaningful milestone for the program. Ovarian cancer remains one of the deadliest cancers affecting women, and patients with recurrent disease face limited treatment options and poor outcomes. While this Phase 1 study is primarily designed to evaluate safety, we are highly encouraged that five patients have surpassed one year of survival following treatment, with one patient having survived beyond two years. Typically, these highly pre-treated patients survive a matter weeks. These are precisely the kinds of signals we hoped to see at this stage. We look forward to further evaluating this novel solid tumor-specific CAR-T therapy as enrollment progresses."
About Lira-cel, Anixa's CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-and-moffitt-cancer-center-advance-ovarian-cancer-car-t-clinical-trial-to-highest-dose-level-to-date-302817267.html
SOURCE Anixa Biosciences, Inc.